City
Epaper

Noida: Families of COVID patients touch feet of CMO, ask for Remdesivir

By ANI | Updated: April 28, 2021 10:25 IST

Amid the shortage of medical supplies due to the worrying rise in COVID-19 cases, families of COVID-19 patients in Noida were seen touching the feet of the Chief Medical Officer asking for essential medicines.

Open in App

Amid the shortage of medical supplies due to the worrying rise in COVID-19 cases, families of COVID-19 patients in Noida were seen touching the feet of the Chief Medical Officer asking for essential medicines.

In the video that made rounds on the internet, relatives were seen touching the feet of CMO Deepak Ohri, requesting that they be provided with the anti-viral drug Remdesivir.

As per the union health ministry, there are currently 3,04,199 active COVID-19 cases in Uttar Pradesh, one of the highest in the country.

As COVID-19 cases peaked amid the second wave, several states complained about shortages of Remdesivir.

The central government had on Saturday allocated supply of Remdesivir to 19 states/union territories with a high burden of COVID-19 cases.

Seven major pharmaceutical compes have also reduced the maximum retail price (MRP) of the anti-viral drug.

As per the revised price of major brands of Remdesivir injection 100mg/Vial', Cadila Healthcare Ltd's REMDAC which was earlier available at Rs 2,800, has been reduced to Rs 899.

The price of Syngene International Ltd's RemWin is reduced to Rs 2,450 from Rs 3,950. Dr Reddy's Laboratories Ltd's REDYX will be available at Rs 2,700 instead of Rs 5,400.

Cipla Ltd's CIPREMI will now be available at Rs 3,000 instead of Rs 4,000, Maylan Pharmaceuticals Pvt Ltd's DESREM will be available at Rs 3400 instead of Rs 4,800, Jubilant Generics Ltd's JUBI-R will be available at Rs 3,400 instead of Rs 4,700 and Hetero Healthcare Ltd's COVIFOR will be available at Rs 3,490 instead of Rs 5,400.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Cadila HealthcareSyngene international ltdDeepak ohri
Open in App

Related Stories

BusinessA Bridge not too far: The man who has the Last Laugh

BusinessZydus gets USFDA's final nod to market antifungal Micafungin for injection

NationalCOVID-19: Pharma companies slash Remdesivir injection prices after govt intervention

HealthSyngene joins global consortium on Covid-19 testing research

NationalAfter used PPE kit found outside hospital, GB Nagar district admin launches probe

National Realted Stories

NationalCentre approves mitigation, recovery and reconstruction projects worth Rs 4645.60 crore

NationalRajasthan: Steady decline in crime over last two years, claims police

NationalMaha: Five Dussehra rallies to be held tomorrow; all eyes on Uddhav Thackeray and Eknath Shinde

NationalCentre grants Rs 260.56 crore for rebuilding Wayanad hit by landslide

National‘Deep insult to freedom struggle’: Congress on honouring RSS